Allena Pharmaceuticals Obtains $53,000,000 Series C Financing Round

  • Feed Type
  • Date
    12/9/2015
  • Company Name
    Allena Pharmaceuticals
  • Mailing Address
    One Newton Executive Park Newton, MA 02462 USA
  • Company Description
    Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.
  • Website
    http://www.allenapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $53,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Allena intends to use the proceeds from the financing to advance its lead product candidate, ALLN-177 for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, into Phase 3 clinical trials. The proceeds will also be used to explore additional indications for ALLN-177, including oxalate nephropathy and primary hyperoxaluria, and to develop new product candidates utilizing Allena’s non-systemic oral protein therapeutic platform.
  • M&A Terms
  • Venture Investor
    Partner Fund Management
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    Wellington Management Company
  • Venture Investor
    Frazier Healthcare Partners
  • Venture Investor
    HBM BioCapital
  • Venture Investor
    Pharmstandard